Lonza: Strong H1 Momentum, 14.7% CER Sales Growth, 33.3% CORE EBITDA Margin

 . In H1 2021, Lonza continued its strong performance with 14.7%^1 sales growth and 33.3% CORE EBITDA margin, despite

    headwinds arising from COVID-19 
  . Continued focus on growth CAPEX investments, supported by strong business pipeline 
  . Expanded collaborations to support COVID-19 programs including Moderna 
  . Divestment of Specialty Ingredients business completed on 1 July 2021 
  . Path forward for a sustainable remediation project agreed for Gamsenried (CH) legacy landfill site will allow Lonza 
    to proceed with its ambitious sustainability agenda 
  . 2021 Outlook: CER sales growth guidance revised upwards to mid-teens. CORE EBITDA margin improvement in line with 
    Mid-Term Guidance trajectory 

Lonza confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales 
growth. The company also anticipates a CORE EBITDA margin improvement in line with the Mid-Term Guidance trajectory, as 
guided at the beginning of the year. The 2021 Outlook assumes a similar level of COVID-related impacts, no significant 
adverse impact on demand and no further disruptions in supply chain or business operations. 
https://www.marketscreener.com/quote/stock/LONZA-GROUP-AG-2956013/news/EQS-Adhoc-Lonza-Reports-Strong-Momentum-in-H1-2021-with-14-7-CER-Sales-Growth-and-33-3-CORE-EBI-35927986/